Virtu Financial LLC Genprex, Inc. Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.37 - $1.04 $22,682 - $63,757	61,305 New	61,305 $24,000
Q2 2022 Aug 09, 2022	BUY	$1.28 - $2.31 $11,608 - $20,949	9,069 Added 43.94%	29,710 $41,000
Q1 2022 May 17, 2022	SELL	$1.82 - $3.5 $190,270 - $365,904	-104,544 Reduced 83.51%	20,641 $47,000
Q4 2021 Feb 17, 2022	BUY	$1.21 - $2.7 $100,748 - $224,810	83,263 Added 198.61%	125,185 $164,000
Q3 2021 Nov 12, 2021	BUY	$2.59 - $3.36 $108,577 - $140,857	41,922 New	41,922 $112,000
Q2 2021 Sep 17, 2021	SELL	$3.11 - $4.87 $119,884 - $187,728	-38,548 Closed	0 $0
Q1 2021 May 19, 2021	BUY	$3.66 - $7.67 $80,582 - $168,870	22,017 Added 133.19%	38,548 $166,000
Q4 2020 Feb 24, 2021	BUY	$3.03 - $5.51 $8,147 - $14,816	2,689 Added 19.43%	16,531 $69,000
Q3 2020 Dec 11, 2020	SELL	$2.9 - $4.29 $48,615 - $71,917	-16,764 Reduced 54.77%	13,842 $47,000
Q2 2020 Aug 07, 2020	BUY	$1.99 - $3.64 $60,905 - $111,405	30,606 New	30,606 $96,000
Q2 2018 Jul 30, 2018	SELL	$3.84 - $15.9 $61,589 - $255,020	-16,039 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$3.84 - $15.9 $61,589 - $255,020	16,039 New	16,039 $123,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.